Research ArticleClinical Studies
Open Access

Analysis of Clinical Benefit Using DNG64-CAR-V Chimeric Tumor Targeted Amphotropic RNA Vector in CCNG1 Expressing Cancers

SANT P. CHAWLA, SAMANTHA JEFFREY, SKYLER S. PANG, ROBIN L. JONES, STEFAAN W. VAN GOOL, TIMO HUBER, JENNIFER KOSMAL, NEAL S. CHAWLA, RHEANNA CARTER, CHARLES B. SIMONE, KAMBIZ NAEL, HOWARD BRUCKNER, ANNA GATTANI, PAUL Y. SONG, FREDERICK L. HALL and ERLINDA M. GORDON
Anticancer Research April 2026, 46 (4) 2025-2034; DOI: https://doi.org/10.21873/anticanres.18091

Article Information

vol. 46 no. 4 2025-2034
DOI 
https://doi.org/10.21873/anticanres.18091
PMID 
41895777
Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received January 20, 2026
  • Revision received February 3, 2026
  • Accepted February 4, 2026
  • Published online March 27, 2026.
Copyright & License 
Copyright © 2026 The Author(s). Published by the International Institute of Anticancer Research. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Author Information

  1. SANT P. CHAWLA1,
  2. SAMANTHA JEFFREY1,
  3. SKYLER S. PANG1,
  4. ROBIN L. JONES2,
  5. STEFAAN W. VAN GOOL3,
  6. TIMO HUBER3,
  7. JENNIFER KOSMAL3,
  8. NEAL S. CHAWLA1,
  9. RHEANNA CARTER4,
  10. CHARLES B. SIMONE II5,
  11. KAMBIZ NAEL6,
  12. HOWARD BRUCKNER7,
  13. ANNA GATTANI7,
  14. PAUL Y. SONG8,
  15. FREDERICK L. HALL9,10 and
  16. ERLINDA M. GORDON1,9,10⇑
  1. 1 Department of Medical Oncology, Cancer Center of Southern California/Sarcoma Oncology Center, Santa Monica, CA, U.S.A.;
  2. 2Department of Medical Oncology, Royal Marsden Hospital and Institute of Cancer Research, London, U.K.;
  3. 3Department of Immunotherapy and Translational Medicine, IOZK Immun-Onkologisches Zentrum Köln, Cologne, Germany;
  4. 4Department of Research and Development, BostonGene Corporation, Waltham, MA, U.S.A.;
  5. 5Department of Radiation Oncology, New York Proton Center, New York, NY, U.S.A.;
  6. 6Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, U.S.A.;
  7. 7Department of Medical Oncology, Bruckner Oncology, New York, NY, U.S.A.;
  8. 8NKGen Biotech, Inc., Santa Ana, CA, U.S.A.;
  9. 9Department of Research and Development, Aveni Foundation, Santa Monica, CA, U.S.A.;
  10. 10Department of Medical Oncology, Delta Next-Gene, LLC, Santa Monica, CA, U.S.A.
  1. Erlinda M. Gordon, 2811 Wilshire Blvd., Suite 414, Santa Monica CA 90403, U.S.A. Tel: +1 3105529999 (Office); +1 8187263278 (Mobile), e-mail: egordon{at}sarcomaoncology.com
View Full Text

Statistics from Altmetric.com

Cited By...

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Analysis of Clinical Benefit Using DNG64-CAR-V Chimeric Tumor Targeted Amphotropic RNA Vector in CCNG1 Expressing Cancers
SANT P. CHAWLA, SAMANTHA JEFFREY, SKYLER S. PANG, ROBIN L. JONES, STEFAAN W. VAN GOOL, TIMO HUBER, JENNIFER KOSMAL, NEAL S. CHAWLA, RHEANNA CARTER, CHARLES B. SIMONE, KAMBIZ NAEL, HOWARD BRUCKNER, ANNA GATTANI, PAUL Y. SONG, FREDERICK L. HALL, ERLINDA M. GORDON
Anticancer Research Apr 2026, 46 (4) 2025-2034; DOI: 10.21873/anticanres.18091
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords